Aduro’s proprietary technologies (STING Pathway Activators and B-select monoclonal antibodies) have the potential to transform the current immunotherapy and cancer care landscape.

Aduro is developing novel therapies that are designed to induce highly targeted, potent and sustained immune responses against a variety of cancers. Through our STING Pathway Activator andB-selecttechnologies, we are poised to fulfill our mission to stay at the forefront of discovery, development and commercialization of immunotherapies, alone or in combination, that have the potential to make transformative advances in the treatment of challenging diseases.

In addition, Aduro has established significant collaboration agreements with leading pharmaceutical and research institutions for  its technologies, further validating the strength and depth of Aduro’s capabilities.

STING Platform

B-select Platform